PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 31004704-6 2019 In addition, TMS activated the AHR more potently (EC50 in a reporter gene assay 2.0 muM) and induced AHR-mediated induction of cytochrome P450 1A1 (CYP1A1) activity (EC50 value of 0.7 muM) more than resveratrol and the other analogues tested. Resveratrol 199-210 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 127-146 32847114-6 2020 We initially characterized resveratrol-aspirin derivatives as products that can inhibit cytochrome P450 Family 1 Subfamily A Member 1 (CYP1A1) activity, DNA methyltransferase (DNMT) activity, and cyclooxygenase (COX) activity. Resveratrol 27-38 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 88-133 32847114-6 2020 We initially characterized resveratrol-aspirin derivatives as products that can inhibit cytochrome P450 Family 1 Subfamily A Member 1 (CYP1A1) activity, DNA methyltransferase (DNMT) activity, and cyclooxygenase (COX) activity. Resveratrol 27-38 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 135-141 32111491-1 2020 Resveratrol modulates the transcription factor NF-kappaB, cytochrome P450 isoenzyme CYP1A1, expression and activity of cyclooxygenase (COX) enzymes, Fas/Fas ligand mediated apoptosis, p53, mTOR and cyclins and various phospho-diesterases resulting in an increase in cytosolic cAMP levels. Resveratrol 0-11 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 84-90 31004704-6 2019 In addition, TMS activated the AHR more potently (EC50 in a reporter gene assay 2.0 muM) and induced AHR-mediated induction of cytochrome P450 1A1 (CYP1A1) activity (EC50 value of 0.7 muM) more than resveratrol and the other analogues tested. Resveratrol 199-210 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 148-154 27162022-5 2016 Resveratrol cotreatment resulted inhibition of testicular cytochrome P4501A1 (CYP1A1) expression, which is the major B(a)P metabolizing agent for BPDE-DNA adduct formation. Resveratrol 0-11 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 58-76 27162022-8 2016 Our findings cumulatively suggest that resveratrol inhibits conversion of B(a)P into BPDE by modulating the transcriptional regulation of CYP1A1 and acting as an antioxidant thus prevents B(a)P-induced oxidative stress and testicular apoptosis. Resveratrol 39-50 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 138-144 28049037-0 2017 Role of CYP1A1 in the biological activity of methylated resveratrol analogue, 3,4,5,4"-tetramethoxystilbene (DMU-212) in ovarian cancer A-2780 and non-cancerous HOSE cells. Resveratrol 56-67 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 8-14 28049037-1 2017 The role of CYP1A1 and CYP1B1 enzymes in the biotransformation and biological activity of the methylated resveratrol analogue, 3,4,5,4"-tetramethoxystilbene (DMU-212) is still elusive. Resveratrol 105-116 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 12-18 27162022-5 2016 Resveratrol cotreatment resulted inhibition of testicular cytochrome P4501A1 (CYP1A1) expression, which is the major B(a)P metabolizing agent for BPDE-DNA adduct formation. Resveratrol 0-11 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 78-84 27162022-6 2016 Resveratrol also significantly decreased the B(a)P-induced AhR protein level, its nuclear translocation and subsequent promoter activation, thereby decreased the expression of CYP1A1. Resveratrol 0-11 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 176-182 25407017-0 2015 Design and synthesis of resveratrol-salicylate hybrid derivatives as CYP1A1 inhibitors. Resveratrol 24-35 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 69-75 27265259-1 2016 Many cytochrome P450 1A1 and 1B1 (CYP1A1 and CYP1B1) inhibitors, such as resveratrol, have planar, hydrophobic, aromatic rings in their structure and exhibit anti-cancer activity. Resveratrol 73-84 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 5-32 27265259-1 2016 Many cytochrome P450 1A1 and 1B1 (CYP1A1 and CYP1B1) inhibitors, such as resveratrol, have planar, hydrophobic, aromatic rings in their structure and exhibit anti-cancer activity. Resveratrol 73-84 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 34-40 25407017-3 2015 Using HepG2 cells, we evaluated (a) the inhibition of TCDD-mediated induction of CYP1A1 exerted by resveratrol-aspirin derivatives using the EROD assay, and (b) CYP1A1 mRNA in vitro. Resveratrol 99-110 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 81-87 22863525-0 2012 Design, synthesis and evaluation of the inhibitory selectivity of novel trans-resveratrol analogues on human recombinant CYP1A1, CYP1A2 and CYP1B1. Resveratrol 72-89 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 121-127 26666021-11 2015 The expression of CYP1Al protein was increased after dioscin treatment, and resveratrol, an AhR antagonist, could downregulate the expression of CYP1A1. Resveratrol 76-87 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 145-151 23873331-5 2013 In order to test possible correlation between expression of CYP1A1, CYP1B1 and MnSOD and modulators of their activity, cytotoxicity of resveratrol and its promising hydroxylated analogue 3,3",4,4",5,5"-trans-hexahydroxystilbene against cell lines used in experiment was assayed. Resveratrol 135-146 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 60-66 23288144-7 2013 In addition, blocking of AhR activation by resveratrol, a well-known AhR antagonist, prevented the SUN-induced CYP1A1 gene expression, further confirms the involvement of AhR. Resveratrol 43-54 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 111-117 21262253-6 2011 In addition, the tanshinone-induced CYP1A1/2 expression was abolished by the aryl hydrocarbon receptor (AhR) antagonist resveratrol, suggesting an AhR dependent transcription mechanism. Resveratrol 120-131 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 36-42 20732341-7 2010 Moreover, the AhR antagonist, resveratrol, inhibited the increase in CYP1A1 activity by harman. Resveratrol 30-41 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 69-75 20846786-3 2010 Kaempferol or resveratrol inhibited dioxin-induced cytochrome P450 1A1 (CYP1A1) and CYP1B1 expression levels and recruitment of AHR, ERalpha and co-activators to CYP1A1 and CYP1B1. Resveratrol 14-25 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 51-70 20846786-3 2010 Kaempferol or resveratrol inhibited dioxin-induced cytochrome P450 1A1 (CYP1A1) and CYP1B1 expression levels and recruitment of AHR, ERalpha and co-activators to CYP1A1 and CYP1B1. Resveratrol 14-25 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 72-78 20846786-3 2010 Kaempferol or resveratrol inhibited dioxin-induced cytochrome P450 1A1 (CYP1A1) and CYP1B1 expression levels and recruitment of AHR, ERalpha and co-activators to CYP1A1 and CYP1B1. Resveratrol 14-25 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 162-168 19811694-6 2009 Resveratrol ranging from 1 to 5 microm could significantly suppress the expressions of cytochrome P450 (CYP) 1A1, CYP1B1 and UDP-glucuronosyltransferase (UGT) 1A1 induced by 7,12-dimethylbenz[a]anthracene (DMBA). Resveratrol 0-11 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 87-112 19371443-5 2009 RT-PCR and western blot analysis showed that both CYP1A1 mRNA and protein expression were increased in a dose-dependent manner following TCDD treatment and AhR antagonist resveratrol (RSV) could reverse this TCDD-induced CYP1A1 expression. Resveratrol 171-182 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 50-56 19376845-0 2009 Resveratrol inhibits dioxin-induced expression of human CYP1A1 and CYP1B1 by inhibiting recruitment of the aryl hydrocarbon receptor complex and RNA polymerase II to the regulatory regions of the corresponding genes. Resveratrol 0-11 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 56-62 19376845-2 2009 Resveratrol (3,4,5-trihydroxystelbine) is a naturally occurring compound that has been shown in a number of studies to inhibit the induction of CYP1A1 and CYP1B1 by dioxin (2,3,7,8-tetrachloro-dibenzo-p-dioxin), but the mechanism(s) of resveratrol inhibition is controversial. Resveratrol 0-11 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 144-150 19376845-2 2009 Resveratrol (3,4,5-trihydroxystelbine) is a naturally occurring compound that has been shown in a number of studies to inhibit the induction of CYP1A1 and CYP1B1 by dioxin (2,3,7,8-tetrachloro-dibenzo-p-dioxin), but the mechanism(s) of resveratrol inhibition is controversial. Resveratrol 236-247 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 144-150 19371443-5 2009 RT-PCR and western blot analysis showed that both CYP1A1 mRNA and protein expression were increased in a dose-dependent manner following TCDD treatment and AhR antagonist resveratrol (RSV) could reverse this TCDD-induced CYP1A1 expression. Resveratrol 171-182 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 221-227 19371443-5 2009 RT-PCR and western blot analysis showed that both CYP1A1 mRNA and protein expression were increased in a dose-dependent manner following TCDD treatment and AhR antagonist resveratrol (RSV) could reverse this TCDD-induced CYP1A1 expression. Resveratrol 184-187 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 50-56 19371443-5 2009 RT-PCR and western blot analysis showed that both CYP1A1 mRNA and protein expression were increased in a dose-dependent manner following TCDD treatment and AhR antagonist resveratrol (RSV) could reverse this TCDD-induced CYP1A1 expression. Resveratrol 184-187 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 221-227 17440990-4 2007 Results from this study indicate that trans-resveratrol analogues in which the hydroxy groups are substituted by methoxy groups exhibit a remarkably stronger inhibitory effect towards CYP1A1 in comparison to the parent compound. Resveratrol 38-55 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 184-190 17440990-2 2007 The aim of our research was to determine and compare the inhibitory effect of naturally occurring analogues of trans-resveratrol on the catalytic activities of human recombinant CYP1A1 and CYP1B1. Resveratrol 111-128 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 178-184 15893423-5 2005 alpha-NF inhibited resveratrol-induced CYP1A1 expression without interfering cell differentiation and apoptosis. Resveratrol 19-30 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 39-45 15893423-1 2005 Resveratrol induces apoptosis and regulates CYP1A1 and CYP1B1 expression in human medulloblastoma cells. Resveratrol 0-11 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 44-50 18001219-6 2007 The TCDD-induced binding of the AhR to COX-2 and CYP1A1 oligonucleotides was repressed by cotreatment with CLA (t10,c12-CLA > c9,t11-CLA), and the AhR antagonists, 3-methoxy-4-naphthoflavone, and resveratrol. Resveratrol 199-210 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 49-55 16484233-7 2006 The catalytic activity of CYP1A1/1B1 was reduced over 95% after exposure to 5,7-DMF, 3",4"-DMF or RV, most effectively by 3",4"-DMF. Resveratrol 98-100 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 26-36 16581943-8 2006 Resveratrol, an AhR antagonist, repressed the induction of CYP1A1 by tBHQ. Resveratrol 0-11 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 59-65 15893423-6 2005 beta-NF could up-regulate resveratrol-induced CYP1A1 expression but not enhance the anti-cancer effects of resveratrol. Resveratrol 26-37 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 46-52 15316568-1 2004 Resveratrol inhibits PAH bioactivation through reduced expression of the CYP1A1 and CYP1B1 genes in human bronchial epithelial cells. Resveratrol 0-11 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 73-79 15649641-11 2005 Resveratrol and furafylline exhibited dose-dependent decreases in CYP1A1 and CYP1A2 enzyme activities with IC50 values of 1.89 and 0.79 microM, respectively. Resveratrol 0-11 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 66-72 15142886-3 2004 Resveratrol strongly inhibited the TCDD-induced aryl hydrocarbon receptor (AhR) DNA binding activity, the expression of CYP1A1 and CYP1B1 and their catalytic activities in MCF-10A cells. Resveratrol 0-11 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 120-126 15142886-0 2004 Resveratrol inhibits TCDD-induced expression of CYP1A1 and CYP1B1 and catechol estrogen-mediated oxidative DNA damage in cultured human mammary epithelial cells. Resveratrol 0-11 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 48-54 15142886-6 2004 Our data suggest that CYP1A1- and CYP1B1-catalyzed catechol estrogen formation might play a key role in TCDD-induced oxidative damage, and resveratrol can act as a potential chemopreventive against dioxin-induced human mammary carcinogenesis by blocking the metabolic formation of the catechol estrogens and scavenging the ROS generated during their redox cycling. Resveratrol 139-150 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 22-28 11597580-7 2001 Actinomycin D chase experiments in T47D cells showed that resveratrol and dehydroepiandrosterone both increased the rate of CYP1A1 mRNA degradation, whereas resveratrol did not affect CYP1A1-dependent activity in cells pretreated with TCDD for 18 hr. Resveratrol 58-69 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 124-130 15276085-8 2004 In addition, the metabolism of trans-resveratrol into these two metabolites was catalyzed by recombinant human CYP1A1, CYP1A2 and CYP1B1. Resveratrol 31-48 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 111-117 15182955-0 2004 Differential regulation of CYP1A1 and CYP1B1 expression in resveratrol-treated human medulloblastoma cells. Resveratrol 59-70 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 27-33 15182955-2 2004 CYP1A1 and 1B1 are involved in resveratrol-mediated tumor suppression but their expression in medulloblastoma cells and their relevance to anti-medulloblastoma activity of resveratrol have not been described. Resveratrol 31-42 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 0-14 15182955-3 2004 The statuses of CYP1A1 and 1B1 in UW228-3 medulloblastoma cells without and with resveratrol treatments were elucidated in this study with ethoxyresorufin O-deethylation assay, followed by RT-PCR, immunocytochemical staining and Western blot hybridization. Resveratrol 81-92 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 16-30 15182955-4 2004 CYP1A1/1B1 enzymatic activity was low in UW228-3 cells but became several folds higher upon resveratrol treatments. Resveratrol 92-103 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 0-10 15182955-6 2004 Accompanied by the increased fraction of apoptosis, enhanced CYP1A1 and downregulated CYP1B1 were observed in resveratrol-treated cells in time- and dose-related fashions. Resveratrol 110-121 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 61-67 15182955-7 2004 Our results demonstrate for the first time that in the medulloblastoma cell system, CYP1A1 upregulation is paralleled with resveratrol-induced differentiation and apoptosis, while CYP1B1 may not be an essential element in metabolic activation of resveratrol in those cells. Resveratrol 123-134 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 84-90 15182955-8 2004 CYP1A1 and 1B1 are resveratrol response genes and potential chemosensitive markers of medulloblastoma cells. Resveratrol 19-30 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 0-14 15044623-7 2004 CYP1A1 modulation was abolished by a cotreatment with resveratrol, an established AhR antagonist, arguing for AhR activation by U0126. Resveratrol 54-65 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 0-6 11597580-0 2001 Involvement of a post-transcriptional mechanism in the inhibition of CYP1A1 expression by resveratrol in breast cancer cells. Resveratrol 90-101 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 69-75 11597580-1 2001 Resveratrol decreases basal and induced CYP1A1 mRNA/protein levels in both in vitro and in vivo models, and some studies suggest that resveratrol acts as an aryl hydrocarbon receptor (AhR) antagonist. Resveratrol 0-11 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 40-46 11597580-2 2001 Treatment of T47D or MCF-7 cells with 10 microM resveratrol inhibited induction of CYP1A1 mRNA and CYP1A1-dependent activity after treatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), as previously reported. Resveratrol 48-59 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 83-89 11597580-2 2001 Treatment of T47D or MCF-7 cells with 10 microM resveratrol inhibited induction of CYP1A1 mRNA and CYP1A1-dependent activity after treatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), as previously reported. Resveratrol 48-59 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 99-105 15517885-8 2004 In vivo, resveratrol blocks the multistep process of carcinogenesis at various stages: it blocks carcinogen activation by inhibiting aryl hydrocarbon-induced CYP1A1 expression and activity, and suppresses tumor initiation, promotion and progression. Resveratrol 9-20 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 158-164 15162144-3 2004 This was compared to the effect of resveratrol on the expression of the cytochrome P450 (CYP) genes CYP1A1 and CYP1B1 and the formation of B[a]P metabolites. Resveratrol 35-46 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 100-106 15162144-5 2004 Supporting this result, resveratrol was shown to inhibit CYP1A1 and CYP1B1 gene expression, as measured by real-time reverse transcriptase-polymerase chain reaction. Resveratrol 24-35 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 57-63 14707267-8 2003 Treatment of sensitive cell lines with 10 micro M resveratrol, an inhibitor of CYP1A1 induction, in combination with either 1 or 10 micro M 5F-203 showed an ablation of the observed CYP1A1, but not CYP1B1 mRNA induction in parallel with a decreased sensitivity to 5F-203. Resveratrol 50-61 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 79-85 14707267-8 2003 Treatment of sensitive cell lines with 10 micro M resveratrol, an inhibitor of CYP1A1 induction, in combination with either 1 or 10 micro M 5F-203 showed an ablation of the observed CYP1A1, but not CYP1B1 mRNA induction in parallel with a decreased sensitivity to 5F-203. Resveratrol 50-61 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 182-188 11959854-7 2002 Furthermore we demonstrated that resveratrol, an antagonist of the aryl hydrocarbon (Ah) receptor, inhibited the induction of both CYP1A1 promoter activity and mRNA by oltipraz, supporting the involvement of the Ah receptor in this induction. Resveratrol 33-44 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 131-137 11714871-0 2001 Differential inhibition and inactivation of human CYP1 enzymes by trans-resveratrol: evidence for mechanism-based inactivation of CYP1A2. Resveratrol 66-83 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 50-54 11714871-2 2001 A potential mechanism for this effect by trans-resveratrol is inhibition of DMBA-bioactivating cytochrome P450 (CYP) enzymes such as CYP1B1, CYP1A1, and CYP1A2. Resveratrol 41-58 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 141-147 11714871-4 2001 trans-Resveratrol decreased 7-ethoxyresorufin O-dealkylation activity catalyzed by human recombinant CYP1B1, CYP1A1, and CYP1A2 in a concentration-dependent manner and by a mixed type of inhibition. Resveratrol 0-17 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 109-115 11714871-10 2001 In summary, trans-resveratrol differentially inhibited human CYP1 enzymes and this occurred by two distinct mechanisms: direct inhibition (mainly CYP1B1 and CYP1A1) and mechanism-based inactivation (CYP1A2). Resveratrol 12-29 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 61-65 11714871-10 2001 In summary, trans-resveratrol differentially inhibited human CYP1 enzymes and this occurred by two distinct mechanisms: direct inhibition (mainly CYP1B1 and CYP1A1) and mechanism-based inactivation (CYP1A2). Resveratrol 12-29 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 157-163 11597580-8 2001 These data suggest that resveratrol inhibits CYP1A1 via an AhR-independent post-transcriptional pathway. Resveratrol 24-35 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 45-51 11480665-0 2001 The effects of resveratrol on CYP1A1 expression and aryl hydrocarbon receptor function in vitro. Resveratrol 15-26 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 30-36 11279601-6 2001 Resveratrol inhibited both the constitutive and the induced expression of CYP1A1 and CYP1B1 in a dose-dependent manner. Resveratrol 0-11 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 74-80 11454723-3 2001 Of these flavonoids, resveratrol produced the greatest increase in CYP1A1-mediated luciferase activity (10-fold), whereas GTE, apigenin, curcumin, and kaempferol produced 2- to 3-fold increases in activity. Resveratrol 21-32 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 67-73 9865727-6 1998 The increase in CYP1A1 enzyme activity induced by TCDD was inhibited by resveratrol. Resveratrol 72-83 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 16-22 10496959-0 1999 Inhibition of aryl hydrocarbon-induced cytochrome P-450 1A1 enzyme activity and CYP1A1 expression by resveratrol. Resveratrol 101-112 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 39-59 10496959-0 1999 Inhibition of aryl hydrocarbon-induced cytochrome P-450 1A1 enzyme activity and CYP1A1 expression by resveratrol. Resveratrol 101-112 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 80-86 10496959-3 1999 Resveratrol competitively inhibited, in a concentration-dependent manner, the activity of the carcinogen activating enzymes cytochrome P-450 (CYP)1A1/CYP1A2 in microsomes and intact HepG2 cells. Resveratrol 0-11 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 124-149 10496959-4 1999 Resveratrol inhibited the B[a]P-induced expression of the CYP1A1 gene, as measured at the mRNA and transcriptional levels. Resveratrol 0-11 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 58-64 10496959-5 1999 Resveratrol abolished the binding of B[a]P-activated nuclear aryl hydrocarbon receptor to the xenobiotic-responsive element of the CYP1A1 promoter but did not itself bind to the receptor. Resveratrol 0-11 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 131-137 10496959-6 1999 Resveratrol was also effective in inhibiting CYP1A1 transcription induced by the aryl hydrocarbon dimethylbenz[a]anthracene in human mammary carcinoma MCF-7 cells. Resveratrol 0-11 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 45-51 10496959-7 1999 These data demonstrate that resveratrol inhibits aryl hydrocarbon-induced CYP1A activity in vitro by directly inhibiting CYP1A1/1A2 enzyme activity and by inhibiting the signal transduction pathway that up-regulates the expression of carcinogen activating enzymes. Resveratrol 28-39 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 121-127 10496962-4 1999 Resveratrol inhibits the transactivation of several dioxin-inducible genes including cytochrome P-450 1A1 and interleukin-1beta, both ex vivo and in vivo. Resveratrol 0-11 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 85-105 10448061-0 1999 Resveratrol is a selective human cytochrome P450 1A1 inhibitor. Resveratrol 0-11 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 33-52 9865727-0 1998 Resveratrol inhibits transcription of CYP1A1 in vitro by preventing activation of the aryl hydrocarbon receptor. Resveratrol 0-11 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 38-44 9865727-3 1998 Resveratrol inhibited the increase in cytochrome P450 (CYP) 1A1 mRNA caused by the AHR ligand 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in a concentration-dependent manner. Resveratrol 0-11 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 38-63 9865727-4 1998 The induction of transcription of an aryl hydrocarbon-responsive reporter vector containing the CYP1A1 promoter by TCDD was likewise inhibited by resveratrol. Resveratrol 146-157 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 96-102 9865727-5 1998 Resveratrol also inhibited the constitutive level of CYP1A1 mRNA and reporter vector transcription in HepG2 cells. Resveratrol 0-11 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 53-59 9865727-9 1998 These data demonstrate that resveratrol inhibits CYP1A1 expression in vitro, and that it does this by preventing the binding of the AHR to promoter sequences that regulate CYP1A1 transcription. Resveratrol 28-39 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 49-55 9865727-9 1998 These data demonstrate that resveratrol inhibits CYP1A1 expression in vitro, and that it does this by preventing the binding of the AHR to promoter sequences that regulate CYP1A1 transcription. Resveratrol 28-39 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 172-178